EUVIMEDEUVIMED entdecken
Crossref

COVID-19 Infection Relative Risk Reduction versus Absolute Risk Reduction Since 2023 to 2024 in a General Medicine Office in Toledo (Spain)

Jose Luis Turabian

Medical - Clinical - Research · 2025

DOI: 10.52106/3069-9088.1005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical - Clinical - Research, 2025. Verfasst von Jose Luis Turabian.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The expression of the true impact of COVID-19 prevention measures in daily practice on the population (public health measures, vaccination, natural immunity) can be confusing when presented as relative risk reduction (RRR) or absolute risk reduction (ARR).

Objective

To compare the RRR with ARR of SARS-CoV-2 infections, associated with acquired immunity by vaccination and/or infection since 2023 to 2024. Material and methods: Comparison of secondary data of COVID-19 infection cases in since 2023 to 2024 years of previous studies carried out in the same population of patients treated in a general medicine office in Toledo, Spain. For the calculation of RRR and ARR of SARS-CoV-2 infections, cases in 2023 were considered as control group with respect to cases in 2024.

Results

For the total number of COVID-19 cases (>=14 years) from 2023 to 2024 [In 2023-2024 omicron subvariants were dominant; Fourth dose (second booster) was inoculated in fall-winter 2022-2023; Fifth dose (third booster) was administered in fall-winter 2023-2024]]: an RRR of 25% and an ARR of 1% were found. For all the selected variables studied, the ARRs were always much lower, somewhat lower, or occasionally equal to the RRR.

Conclusion

Expressing the reduction in the risk of COVID-19 as RRR when comparing incidence rates in 2024 versus 2023 shows an exceptionally striking appearance of risk reduction that is not present in its expression as ARR. Presenting results in terms of both ARR and RRR is more comprehensive, allowing both an estimation of the intrinsic preventive efficacy of hybrid immunity and its efficacy during translation to the real world.

Zitieren

APA

Turabian, J. L. (2025). COVID-19 Infection Relative Risk Reduction versus Absolute Risk Reduction Since 2023 to 2024 in a General Medicine Office in Toledo (Spain). Medical - Clinical - Research. https://doi.org/10.52106/3069-9088.1005

Vancouver

Turabian JL. COVID-19 Infection Relative Risk Reduction versus Absolute Risk Reduction Since 2023 to 2024 in a General Medicine Office in Toledo (Spain). Medical - Clinical - Research. 2025. doi:10.52106/3069-9088.1005

BibTeX
@article{Turabian2025,
  author = {Turabian, Jose Luis},
  title = {COVID-19 Infection Relative Risk Reduction versus Absolute Risk Reduction Since 2023 to 2024 in a General Medicine Office in Toledo (Spain)},
  journal = {Medical - Clinical - Research},
  year = {2025},
  doi = {10.52106/3069-9088.1005}
}
Kostenlos starten →